What will the savings be when this drug goes generic?
Will this drug ease the burden on caregivers?
Does this drug benefit healthy people by lowering everyone's risk?
Check out CEVR Deputy Director Josh Cohen’s update on his upcoming paper rethinking the current discount rate used by traditional CEA entities to undervalue the societal impact of biotech innovations.
Medicines help us feel better, but there are so many other things that make medicines valuable. Learn about the many benefits of medicines and and the ways that insurers overlook their value to all of us.
GCEA is a major advancement in our understanding of societal value. Companies and CEOs can commission their own GCEA studies to help protect patient access to these novel and often life-saving treatments by more clearly conveying their value to society.
NPLB's founder, Peter Kolchinsky, addresses misconceptions about value and highlights a plan for how to protect patient access to the medicines we have today while preserving innovation for those still waiting for a cure.
This white paper explains the difference between GCEA and CEA. GCEA is plain english and makes a case for generalizing cost-effectiveness math to avoid undervaluing medicines. Because if we don't do GCEA, then oversimplified health economics math jeopardizes future medical progress and risks saddling society with preventable costs and illness.